The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations

Background and Objective Over the past 2 years, several drugs have been approved for coronavirus disease 2019 (COVID-19) treatment, but their safety during pregnancy remains poorly understood. This study aims to assess the relative risk of obstetric, neonatal, and infant outcomes associated with the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug safety 2024-03, Vol.47 (3), p.195-204
Hauptverfasser:	Wyszynski, Diego F., Papageorghiou, Aris T., Renz, Cheryl, Metz, Torri D., Hernández-Díaz, Sonia
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral agents Cohort analysis Cohort Studies Coronaviruses COVID-19 COVID-19 Drug Treatment Data collection Disease transmission Drug Safety and Pharmacovigilance Drugs Enrollments Female Gestational age Hospitalization Humans Infant, Newborn Infants Infections Medicine Medicine & Public Health Monoclonal antibodies Mortality NCT NCT05013632 Neonates Obstetrics Pandemics Pharmacology/Toxicology Pregnancy Protocol Registries Safety SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Treatment Outcome Viral diseases Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!